Metabolomic Profiling Reveals Biomarkers in Coronary Heart Disease Comorbidity
Author Information
Author(s): Geng Chunmei, Liang Benhui, Kong Zihan, Feng Lei, Wang Jianhua, Si Qingying, Jiang Pei
Primary Institution: Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China
Hypothesis
A comprehensive metabolomic-based evaluation of comorbidities of coronary heart disease (CHD) is necessary.
Conclusion
The study systematically elucidated the metabolic changes underlying the comorbidities of CHD, providing insight into the mechanisms associated with these alterations.
Supporting Evidence
- 169 healthy subjects and 440 patients with CHD and its comorbidities were analyzed.
- Nine metabolites were identified in the healthy and CHD group.
- Six metabolic pathways were affected by the comorbidities of CHD.
Takeaway
Researchers looked at blood samples from people with heart disease and found specific changes in their metabolism that could help understand their other health problems.
Methodology
Gas chromatography–mass spectrometry was used for metabolite determination, and multivariate statistical analysis was conducted to identify differentially expressed metabolites.
Potential Biases
Potential biases may arise from the single-center design and the specific population studied.
Limitations
The study used a single metabolomic method and a larger sample size is needed for validation.
Participant Demographics
The study included 169 healthy subjects and 440 patients with various comorbidities of CHD.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website